Guangzhou Hanfang Launches ExportGrade Medium Chain Triglycerides for Injection

Domestically Developed API Breaks Global Supply Bottlenecks, Meets International Regulatory Standards

GUANGZHOU, China – September 1, 2026 – Global leading provider of high-end pharmaceutical lipid excipients and specialty APIs, Guangzhou Hanfang Pharmaceutical Company Limited, today officially launches its export-grade medium chain triglycerides (MCT) for injection. This domestically developed product addresses critical supply chain gaps for pharmaceutical and nutraceutical manufacturers worldwide, featuring green production technology, consistent purity levels, and full compliance with international quality standards. With this launch, Guangzhou Hanfang aims to expand its global footprint in the pharmaceutical excipients market, offering reliable local alternatives to imported products. The export-grade MCT for injection is now available for global pre-orders, with mass production and shipping starting in September 2026 .

Core Technological Breakthroughs & Product Highlights

1. Domestic Supply Chain Solution: Guangzhou Hanfang’s MCT for injection breaks long-standing foreign monopolies in high-end pharmaceutical lipid excipients, increasing domestic market share from 10% to 90% since its 2023 launch . This provides global manufacturers with a stable, cost-effective alternative to imported supplies, reducing reliance on international supply chain risks.

2. Green Integrated Production Technology: The product uses a proprietary "supercritical CO₂ extraction-membrane separation-chromatography separation" process, replacing traditional high-pollution manufacturing methods . This ensures environmental sustainability while maintaining consistent product purity and quality.

3. Versatile Application: As an API, solvent, and emulsifier, the export-grade MCT caters to functional food, medical food, and high-end injectable formulation manufacturers, meeting diverse production needs .

Global Compliance & Certifications

To meet global market access requirements, Guangzhou Hanfang’s export-grade MCT for injection holds key international certifications including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI . These certifications ensure the product complies with regulatory standards in the EU, North America, Asia-Pacific, and other major global markets, enabling seamless deployment across international manufacturing facilities.

Availability & Customization Services

The export-grade MCT for injection is now open for global pre-orders through Guangzhou Hanfang’s official website and authorized global distributors . Mass production and worldwide shipping will commence in September 2026. In addition to standard products, the company offers customized solutions including tailored purity levels, packaging specifications, and volume requirements to meet unique customer needs across industries.

Executive Quote

"The launch of our export-grade medium chain triglycerides for injection marks a key milestone in our global expansion strategy," said Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center at Guangzhou Hanfang Pharmaceutical Company Limited . "By combining domestic technological innovation with international compliance, we are able to provide reliable, high-quality products that support global pharmaceutical supply chain resilience and meet the evolving needs of manufacturers worldwide."

Industry Context & Strategic Alignment

According to Grand View Research, the global pharmaceutical excipients market is projected to grow at a steady compound annual growth rate through 2030, driven by increasing demand for high-quality injectable formulations and a focus on supply chain diversification. Guangzhou Hanfang’s launch aligns with this trend, leveraging its national-level research capabilities to address critical industry needs and strengthen its position as a leading global supplier of pharmaceutical lipid excipients .

Future Plans

Looking ahead, Guangzhou Hanfang Pharmaceutical Company Limited will continue to invest in R&D for high-end pharmaceutical lipid excipients, expanding its product portfolio to include more innovative solutions for global markets . The company also plans to enhance its global sales and service network, providing localized support to customers in more than 20 countries and regions where it currently operates.

About Guangzhou Hanfang Pharmaceutical Company Limited

Established in 1998, Guangzhou Hanfang Pharmaceutical Company Limited is a core modern pharmaceutical enterprise under the Guangzhou Pharmaceutical Holdings (GPH) Group, specializing in APIs, pharmaceutical lipid excipients, health products, and technical services . As a national-level specialized, sophisticated, unique, and new "Little Giant" enterprise, it operates the only national-level engineering research center for traditional Chinese medicine (TCM) pharmaceutical processes and new drug development, with over 240 patents and products sold in more than 20 countries . The company’s mission is to achieve technological self-reliance, break "bottleneck" technologies, and ensure the safety of the pharmaceutical supply chain.

For more information, visit the official website at http://byshanhanfang.com/

Contact Information

Company: Guangzhou Hanfang Pharmaceutical Company Limited
Official Website: http://byshanhanfang.com/

© 2026 Guangzhou Hanfang Pharmaceutical Company Limited. All rights reserved.